Synapse - Robert Motzer

Results (1243)

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

Meeting Abstract

Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Meeting Abstract

Choueiri, T. K.; Albiges, L.; McKay, R. R.; Pal, S. K.; Hammers, H. J.; Heng, D. Y. C.; Beckermann, K.; Kasturi, V.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors

Meeting Abstract

Choueiri, T. K.; McGregor, B. A.; Shah, N. J.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Oliver, J. W.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. K.; Suarez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214

Meeting Abstract

Cella, D.; Hamilton, M.; Blum, S. I.; Ivanescu, C.; Williams, A.; Ejzykowicz, F.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial

Meeting Abstract

Carril-Ajuria, L.; Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Hammers, H. J.; Plimack, E. R.; Donskov, F.; Rini, B. I.; Jiang, R.; Lee, C. W.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study

Meeting Abstract

Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
Asia-Pacific Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)

Meeting Abstract

Motzer, R.; George, S.; Merchan, J. R.; Hutson, T. E.; Song, X.; Perini, R. F.; Xie, R.; Bapat, U.; Ebaid, B.; Puente, J.
Asia-Pacific Journal of Clinical Oncology (2022)

Fulltext@MSK | Save